List view / Grid view
A trial comparing co-administration of influenza and COVID-19 vaccines to…
A trial comparing co-administration of influenza and COVID-19 vaccines to COVID-19 vaccine dosing alone found little effect on vaccine efficacy.
New data shows NVX-CoV2373 offered complete protection against severe COVID-19…
New data shows NVX-CoV2373 offered complete protection against severe COVID-19 and 60 percent efficacy against infection with the B.1.351 variant in healthy adults.
The EMA is evaluating whether to lower the age at…
The EMA is evaluating whether to lower the age at which Comirnaty can be administered and Novavax has begun testing its COVID-19 vaccine in paediatric patients.
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s…
The FDA has given Fast Track Designation to NVX-CoV2373, Novavax’s COVID-19 vaccine candidate, created using recombinant nanoparticle technology.
The trial will evaluate the safety and efficacy of the…
The trial will evaluate the safety and efficacy of the Novavax’ NVX-CoV2373 vaccine candidate in approximately 10,000 UK participants.
The Phase II clinical trial to study NVX-CoV2373, the Novavax…
The Phase II clinical trial to study NVX-CoV2373, the Novavax COVID-19 vaccine candidate, has enrolled its first patient.
A Phase I trial conducted by Novavax to test NVX‑CoV2373,…
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.
